Swiss National Bank
RAPP

Swiss National Bank’s Rapport Therapeutics RAPP Stock Holding History

Swiss National Bank’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.77M Buy
56,500
+1,900
+3% +$53.4K ﹤0.01% 1916
2025
Q4 		$1.66M Buy
+54,600
New +$1.51M ﹤0.01% 1957
2025
Q2 		– Sell
-31,900
Closed -$320K – 2405
2025
Q1 		$320K Buy
31,900
+13,900
+77% +$180K ﹤0.01% 2385
2024
Q4 		$319K Buy
+18,000
New +$399K ﹤0.01% 2427

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Swiss National Bank's RAPP Position: Q1 2026 in Review

Swiss National Bank increased its Rapport Therapeutics (RAPP) stake by 3.5% in Q1 2026, buying an estimated $53.4K and bringing the position to 56,500 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1916.

Swiss National Bank first reported a position in RAPP in Q4 2024 and has held it in 4 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Swiss National Bank held 56,500 shares of Rapport Therapeutics worth $1.77M as of Q1 2026.
  • Swiss National Bank bought 1,900 Rapport Therapeutics shares in Q1 2026, an estimated $53.4K.
  • Rapport Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1916 holding.
  • Swiss National Bank first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.